Q-omics provides the consensus-scored GALNT3 profile across patient tissues and cancer cell-line models. GALNT3 expression is associated with patient survival in 24 of 34 cancer types, with the highest sampling consensus in HNSC. Among the 18 cancer types available for tumor–normal comparison, GALNT3 is differentially expressed in 15, with the highest sampling consensus in KIRC. Additionally, GALNT3 protein abundance shows 21,025 significant protein co-abundance associations, with the highest sampling consensus in GBM. Together, these results highlight HNSC, KIRC, and GBM as cancer lineages where GALNT3 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for GALNT3 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes GALNT3 survival associations across molecular data types. GALNT3 RNA expression shows survival associations in the most cancer types (24), followed by mutation status (7) and mass-spec protein abundance (9). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible GALNT3 RNA expression–survival associations across cancer types. High GALNT3 expression shows unfavorable associations in HNSC, UVM, CESC, LGG, LUAD and DLBC. The HNSC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify HNSC as the clearest survival context for GALNT3 RNA expression.
This table summarizes GALNT3 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 15, while mass-spec protein shows differences in 9. The strongest signals are observed in KIRC for RNA and CCRCC for protein.
This table ranks reproducible tumor–normal expression differences for GALNT3. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. GALNT3 shows lower tumor expression in KIRC, KICH and KIRP and higher tumor expression in BLCA, HNSC and LUSC. The KIRC box plot shows higher GALNT3 RNA expression in normal versus tumor tissue (log2 FC = −3.076, t-test p < 0.001).
This table shows molecular features associated with GALNT3 in patient tissues and cancer cell lines. In patient samples, GALNT3 shows the broadest associations at the RNA and protein expression levels, with GBM recurring as the lineage with the largest associated feature set. In cancer cell lines, GALNT3 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in SKIN, while CRISPR and shRNA rows add functional-dependency signals in LUNG_NSCLC_LUAD and LARGE_INTESTINE.
